Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis

Shemer, Avner; Nathansohn, Nir; Trau, Henri

doi:10.1080/09546630500420183

Cited by 66 publications

(46 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While most onychomycosis studies focus on the great toenail, Shemer et al [25], found that there was a statistically significant difference in complete cure rates between the great toenail (23%), as compared to the second (65%), third (51%) and the fourth toenails (67%) [43]. This may be partially attributed to the fact that the hallux is more prone to external trauma [15,44,45] and thus more likely to be infected compared to healthy, non-deformed, toenails [46]. In addition, nail dystrophy may reduce penetration of the drug into its target.…”

Section: Nail Featuresmentioning

confidence: 94%

Prognostic Factors in Onychomycosis Treatment

Lipner

Scher

2014

J Infect Dis Ther

View full text Add to dashboard Cite

Onychomycosis is a common fungal disease of the nail unit with a prevalence of 10% to 12% in the United States. Despite therapeutic innovations in the last few decades, as many as 20-25% of patients do not achieve a complete cure, and 10-53% are reported to relapse after successful treatment. Some of the factors associated with a poor response to onychomycosis have been well studied. They include patient characteristics and morbidities, nail characteristics, and the infecting organism. Therefore, the goal of therapy is to identify these specific prognostic features for each patient and devise an appropriate treatment plan that will allow for the best chance for cure. Scoring systems may be helpful for grading the severity of onychomycosis and predicting the therapeutic outcome.

show abstract

Section: Nail Featuresmentioning

confidence: 94%

Prognostic Factors in Onychomycosis Treatment

Lipner

Scher

2014

J Infect Dis Ther

View full text Add to dashboard Cite

show abstract

“…118,119 Similarly, only limited increases in effi cacy are observed when daily oral therapy is combined with adjunctive therapy including once-weekly topical amorolfi ne or once-daily topical ciclopirox. [120][121][122][123] In each study topical therapy appeared to confer slight improvements in response; however, limited sample sizes restrict their signifi cance and superiority over terbinafi ne alone could not be determined.…”

Section: Onychomycosismentioning

confidence: 99%

Update on terbinafine with a focus on dermatophytoses

Newland¹,

Abdel‐Rahman

2009

CCID

View full text Add to dashboard Cite

Since terbinafi ne was introduced on the world market 17 years ago, it has become the leading antifungal for the treatment of superfi cial fungal infections, aided by unique pharmacologic and microbiologic profi les. This article reviews mode of action, antimycotic spectrum and disposition profi le of terbinafi ne. It examines the data, accumulated over 15 years, on the comparative effi cacy of terbinafi ne (vs griseofulvin, itraconazole, fl uconazole) in the management of the infections for which it is primarily indicated (eg, dermatophytoses) and provides a brief discussion on its use for the treatment of non-dermatophyte infections. Finally, the available data on the newest topical and systemic formulations are introduced.

show abstract

“…Mycological cure rates for combination therapy were reported as 88%, 70%, and 70%, versus rates of 65%, 56%, and 82.6% for terbinafine monotherapy, respectively (42)(43)(44).…”

Section: Accepted Manuscriptmentioning

confidence: 99%